(redirected from immune modulator)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
References in periodicals archive ?
It is registered as an Immune Modulator drug in two countries, with more on the way, and holds several approved and pending patents.
But the potential danger entailed in applying a topical immune modulator to skin already predisposed to the development of malignancy because of prior exposure to carcinogenic therapies warrants a conservative approach until the topical immune modulators have a longer safety track record, he added.
Since its founding in 2005, the Company has worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including MS.
Anakinra, a recombinant formulation of human interleukin-1 receptor antagonist, could become the next immune modulator available for treating people with severe rheumatoid arthritis.
Colby is developing new oral small molecule signal transduction modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain, infectious diseases, and neurodegenerative diseases.
The base technology for the Matrix Immune Modulator (MIM) product has been commercialized by Cook Biotech and has been used in approximately 2 million patients worldwide.
Nasdaq: IDRA) today announced that data from its Phase 1 clinical trial of IMO-2125, its novel immune modulator for the treatment of chronic hepatitis C virus (HCV) infection, in treatment-naove genotype 1 HCV patients will be presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) being held March 30 - April 3, 2011 in Berlin, Germany.
The addition of this antibody made a significant difference in outcomes among these patients, even among those who had previously relapsed or did not respond to initial therapy with immune modulator drugs," said lead study author Thomas Martin, MD, of the University of California, San Francisco.
Nasdaq: IDRA) today announced that data related to IMO-2125, its novel immune modulator for the treatment of chronic hepatitis C virus (HCV) infection, will be presented at the 61st Annual Meeting of the American Association of the Study of Liver Diseases in Boston, Massachusetts October 29 - November 2, 2010.
Imprime PGG is a novel immune modulator with a highly specific mechanism of action that enables the body's own immune cells to kill cancer.
TNIB is focused on the application and commercialization of Lodonal(TM) as a novel immune modulator that can be orally administered once a day.